- AVEO Oncology (NASDAQ:AVEO) has entered into a clinical collaboration with AstraZeneca (AZN) to evaluate the safety and efficacy of AstraZeneca's IMFINZI (durvalumab) in combination with AVEO's FOTIVDA (tivozanib) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study.
- The study costs will be shared equally by both parties. The Phase 1 portion of the study is expected to commence in 2019.
- AVEO shares are up 3% premarket.